Table 3. Outcomes in patients with HBeAg-positive CHB infection stratified by HBV genotype after completing 24 weeks of PegIFN treatment.
| Total (n = 111) | HBV genotype C (n = 91) | HBV non-genotype C (n = 14) | p-value | |
|---|---|---|---|---|
| At end-of-treatment | ||||
| HBV DNA < 2,000 IU/ml | 53 (54.1%) | 42 (53.2%) | 7 (50.0%) | 0.83 |
| HBeAg seroconversion | 26 (25.2%) | 26 (31.0%) | 0 | 0.01 |
| HBsAg loss | 5 (5.1%) | 5 (6.1%) | 0 | 0.36 |
| ALT normalization | 67 (60.4%) | 54 (59.3%) | 12 (64.3%) | 0.06 |
| At 24 weeks of follow-up | ||||
| HBV DNA < 2,000 IU/ml | 42 (41.2%) | 36 (43.4%) | 5 (35.7%) | 0.13 |
| HBeAg seroconversion | 30 (27%) | 28 (30.8%) | 1 (7.1%) | 0.07 |
| HBsAg loss | 8 (7.5%) | 6 (6.8%) | 1 (7.1%) | 0.96 |
| ALT normalization | 67 (60.4%) | 54 (59.3%) | 12 (85.7%) | 0.06 |
PegIFN, pegylated interferon; HBV, hepatitis B virus; CHB, chronic hepatitis B; ALT, alanine aminotransferase.